The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis

•Ocrelizumab phase II trial extension data has 18-month post-drug follow-up.•Annualized relapse rate seems to remain low during the drug-free follow-up.•Infections and adverse events seem to be reduced during drug-free follow-up.•Extended interval dosing may be possible that maintains efficacy and a...

Ausführliche Beschreibung